Inovio Pharma rises on FDA's 'breakthrough' tag for respiratory disease therapy

Inovio Pharmaceuticals

07/09/2023 15:48

** Shares of drug developer Inovio Pharmaceuticals  INO.O 
rise ~4.5% to 45 cents
    ** Co says the U.S. FDA granted "breakthrough therapy"
designation to its experimental therapy to treat Recurrent
Respiratory Papillomatosis (RRP) 
    ** RRP is characterized by the development of small,
wart-like growths, or papillomas, in the respiratory tract
    ** The therapy, INO-3107, had earlier received "orphan drug"
status from the European Commission in May 
    **  "Breakthrough therapy" tag is meant to speed up the
development and review of drugs to treat a serious condition or
unmet medical need
    ** Including session moves, shares down ~70.4% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))